Agreed, if all you are considering is efficacy.
But the high roll over into Lilac suggests that there were no issues with side effects or safety concerns by parents.
The FDA is more likely to approve a new drug, even with limited efficacy, if a) there are no other treatments and 2) there are no safety or tolerance issues.
- Forums
- ASX - By Stock
- ACADIA earnings
Agreed, if all you are considering is efficacy.But the high roll...
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.61 |
Change
0.400(2.63%) |
Mkt cap ! $1.996B |
Open | High | Low | Value | Volume |
$15.51 | $15.82 | $15.46 | $2.639M | 169.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 2099 | $15.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.62 | 404 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 315 | 15.610 |
19 | 2123 | 15.600 |
4 | 378 | 15.590 |
6 | 543 | 15.580 |
6 | 689 | 15.570 |
Price($) | Vol. | No. |
---|---|---|
15.620 | 182 | 8 |
15.630 | 726 | 13 |
15.640 | 759 | 13 |
15.650 | 400 | 3 |
15.660 | 429 | 4 |
Last trade - 13.01pm 30/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
SPONSORED BY The Market Online